Psychemedics PMDI

Psychemedics Corporation provides testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples. The company utilizes patented technology that digests hair and releases trapped substances without destroying them, followed by proprietary enzyme immunoassay and mass spectrometry confirmation. Its services are used by employers, treatment professionals, law enforcement agencies, school administrators, and parents concerned about substance use.

Psychemedics Corporation generates revenue by offering hair drug testing services to customers across various sectors. The company charges fees for screening and confirmation testing of hair samples for substances including cocaine, marijuana, PCP, amphetamines, opioids, synthetic cannabinoids, benzodiazepines, nicotine, fentanyl, fentanyl analogs, and alcohol. Revenue is derived from workplace testing, school-based testing, and direct-to-consumer home testing services such as the PDT-90® product.

The company operates through the following segments:

• Workplace Testing: This segment focuses on providing drug testing services to businesses for pre-employment and employee screening. Psychemedics Corporation markets its services to private sector employers seeking to maintain workplace safety and productivity. The segment emphasizes the advantages of hair testing over urinalysis, including a longer detection window and resistance to sample tampering.
• School Testing: This segment serves educational institutions throughout the United States and in several foreign countries. Psychemedics Corporation offers schools a five-drug screen with mass spectrometry confirmation identical to its workplace testing service. The segment targets school administrators aiming to monitor and deter student substance use.
• Consumer Testing: This segment provides personal drug testing services directly to parents through the PDT-90® home testing kit. The PDT-90® service allows parents to collect a hair sample from their child at home and send it to the laboratory for analysis. It uses the same patented hair testing methodology employed in the company’s workplace and school testing programs.

Psychemedics Corporation holds a competitive position in the drug testing industry due to its proprietary patented technology for hair analysis. The company competes with larger laboratories such as Quest Diagnostics that primarily rely on urinalysis, but differentiates itself through superior detection rates and resistance to evasion tactics. Its FDA-cleared enzyme immunoassays and ownership of screening assay manufacturing give it control over test quality and reliability, which supports its value proposition to customers despite higher pricing relative to urinalysis-based tests.

Psychemedics Corporation serves a diverse customer base including private sector employers, public and private schools, treatment professionals, law enforcement agencies, and individual consumers. Specific customer names are not disclosed in the filing, but the company indicates it has no single customer accounting for 10% or more of total revenue. The company also notes having two customers representing 15% and 12% of accounts receivable as of December 31, 2024, indicating some concentration in its receivables portfolio despite revenue diversification.